ATAI Life Sciences NV
NASDAQ:ATAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
DE |
|
K
|
Kalekim Kimyevi Maddeler Sanayi ve Ticaret AS
IST:KLKIM.E
|
TR |
|
Plexus Corp
NASDAQ:PLXS
|
US |
|
S
|
State Grid Information&Communication Co Ltd
SSE:600131
|
CN |
|
I
|
International Business Machines Corp
XBER:IBM
|
US |
|
P
|
PA Nova SA
WSE:NVA
|
PL |
|
Intrance Co Ltd
TSE:3237
|
JP |
|
M
|
MSC Income Fund Inc
NYSE:MSIF
|
US |
Multiples-Based Value
The Multiples-Based Value of one
ATAI
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 3.54 USD,
ATAI Life Sciences NV
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ATAI Competitors Multiples
ATAI Life Sciences NV Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
1.2B USD | 314.5 | -1.9 | -9.3 | -9.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
837.7B USD | 13.3 | 42.1 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
588.6B USD | 6.2 | 22 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.4 | 11.5 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
227.8B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.3B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.9B USD | 2.6 | 20.5 | 7.8 | 10.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.1 | 7.5 | 8.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD | 2.5 | 17.3 | 7.3 | 9 |